Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion

Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long‐term antitumor activity, and in whom computed tomography (CT) scans revealed a series of su...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Haruhiko, Nishijima, Norihiro, Nasu, Akihiro, Komekado, Hideyuki, Kita, Ryuichi, Kimura, Toru, Kudo, Masatoshi, Osaki, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850300/
https://www.ncbi.nlm.nih.gov/pubmed/30499247
http://dx.doi.org/10.1111/hepr.13294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850300/
https://www.ncbi.nlm.nih.gov/pubmed/30499247
http://dx.doi.org/10.1111/hepr.13294

Ejemplares similares